| Literature DB >> 24098393 |
Bakary Maiga1, Amagana Dolo, Ousmane Touré, Victor Dara, Amadou Tapily, Susana Campino, Nuno Sepulveda, Paul Risley, Nilupa Silva, Nipula Silva, Patrick Corran, Kirk A Rockett, Dominic Kwiatkowski, Taane G Clark, Marita Troye-Blomberg, Ogobara K Doumbo.
Abstract
Malaria still remains a major public health problem in Mali, although disease susceptibility varies between ethnic groups, particularly between the Fulani and Dogon. These two sympatric groups share similar socio-cultural factors and malaria transmission rates, but Fulani individuals tend to show significantly higher spleen enlargement scores, lower parasite prevalence, and seem less affected by the disease than their Dogon neighbours. We have used genetic polymorphisms from malaria-associated genes to investigate associations with various malaria metrics between the Fulanai and Dogon groups. Two cross sectional surveys (transmission season 2006, dry season 2007) were performed. Healthy volunteers from the both ethnic groups (n=939) were recruited in a rural setting. In each survey, clinical (spleen enlargement, axillary temperature, weight) and parasitological data (malaria parasite densities and species) were collected, as well as blood samples. One hundred and sixty six SNPs were genotyped and 5 immunoassays (AMA1, CSP, MSP1, MSP2, total IgE) were performed on the DNA and serum samples respectively. The data confirm the reduced malaria susceptibility in the Fulani, with a higher level of the protective O-blood group, and increased circulating antibody levels to several malaria antigens (p<10(-15)). We identified SNP allele frequency differences between the 2 ethnic groups in CD36, IL4, RTN3 and ADCY9. Moreover, polymorphisms in FCER1A, RAD50, TNF, SLC22A4, and IL13 genes were correlated with antibody production (p-value<0.003). Further work is required to understand the mechanisms underpinning these genetic factors.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24098393 PMCID: PMC3788813 DOI: 10.1371/journal.pone.0075675
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Study characteristics by ethnic group.
| Dogon (n=505, 53.8%) | Fulani (n= 434, 46.2%) | P-value | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N (median) | % (range) | N (median) | %(Range) | ||||||||||||||
| Age (in months) | (204) | (24-744) | (168) | (24-900) | 0.05 | ||||||||||||
| 0-4 years old | 64 | 12.6 | 65 | 15.0 | 0.10 | ||||||||||||
| 5-9 years old | 85 | 16.8 | 78 | 18.0 | |||||||||||||
| 10-15 years old | 86 | 17.0 | 93 | 21.4 | |||||||||||||
| >15 years old | 270 | 53.5 | 198 | 45.6 | |||||||||||||
| Male | 219 | 43.4 | 192 | 44.2 | 0.84 | ||||||||||||
| Rainy season | 332 | 65.7 | 262 | 60.4 | 0.10 | ||||||||||||
| AB0 blood group | |||||||||||||||||
| 0 | 195 | 43.5 | 237 | 56.5 | <10-4 | ||||||||||||
| A | 90 | 20.1 | 87 | 20.8 | |||||||||||||
| B | 136 | 30.4 | 78 | 18.6 | |||||||||||||
| AB | 27 | 6.0 | 17 | 4.1 | |||||||||||||
| Malaria | |||||||||||||||||
| Clinical malaria | 63 | 12.5 | 30 | 6.9 | |||||||||||||
| Asymptomatic | 91 | 18.0 | 79 | 18.2 | |||||||||||||
| None | 351 | 69.5 | 325 | 74.9 | 0.02 | ||||||||||||
| Immunological data | |||||||||||||||||
| AMA1 | (1078) | (0 - 72,770) | (1742) | (2-72,770) | 10-3 | ||||||||||||
| MSP1 | (467) | (0 - 131,800) | (2063) | (19-356,900) | <10-6 | ||||||||||||
| MSP2 | (1427) | (0 - 777,500) | (3164) | (49-777,500) | <10-6 | ||||||||||||
| CSP | (679) | (75-779,700) | (1338) | (0 - 1,387,000) | <10-6 | ||||||||||||
| Total IgE | (1403) | (0 - 21,780) | (1662) | (171-28,960) | 0.02 | ||||||||||||
| Parasitological data | |||||||||||||||||
| Parasite positivity | 108 | 21.6 | 71 | 16.5 | 0.06 | ||||||||||||
| Pf density | (0) | (0 - 3,034,000) | (0) | (0 - 684,400) | 0.02 | ||||||||||||
| Hyperparasitaemia | 56 | 11.1 | 25 | 5.8 | <10-2 | ||||||||||||
| Spleen enlargement | 44 | 8.7 | 133 | 30.6 | <10-6 | ||||||||||||
| Beta-globin HBB SNPs | |||||||||||||||||
| HbS | |||||||||||||||||
| AA genotype | 446 | (96.3) | 420 | (97.9) | |||||||||||||
| AS genotype | 17 | (3.7) | 9 | (2.1) | 0.231 | ||||||||||||
| HbC | |||||||||||||||||
| GG genotype | 341 | (92.4) | 333 | (99.1) | |||||||||||||
|
| 28 | (7.6) | 3 | (0.9) | <10-4 | ||||||||||||
Hyperparasitaemia: parasitemia density greater than 10,000 parasites per microlitre; Parasite positivity: presence of one or more parasite per microlitre; Pf density: number of parasite per microlitre; Spleen enlargement: presence of spleen enlargement; the P-values were calculated from a chi-squared test for qualitative variables and a Mann-Whitney test for continuous variables.
Figure 1The log10 p-values from applying SNP association tests for malaria and clinical phenotypes (from a logistic regression adjusted for age and season).
(a) Clinical malaria.* dashed line represents a p-value of 0.003, polymorphisms are ordered by chromosome (coloured differently) and position (see Tables S1 and S2).(b) Asymptomatic malaria.* dashed line represents a p-value of 0.003, polymorphisms are ordered by chromosome (coloured differently) and position (see Tables S1 and S2). (c) Any malaria. * dashed line represents a p-value of 0.003, polymorphisms are ordered by chromosome (coloured differently) and position (see Tables S1 and S2). (d) Spleen enlargement. * dashed line represents a p-value of 0.003, polymorphisms are ordered by chromosome (coloured differently) and position (see Tables S1 and S2). (a) Parasite positivity. * dashed line represents a p-value of 0.003, polymorphisms are ordered by chromosome (coloured differently) and position (see Tables S1 and S2).
Genetic association tests for malaria and clinical phenotypes by ethnic group.
| Alternative allele frequency, % | Genetic association analysis | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alleles | Dogon | Fulani | Dogon | Fulani | |||||||||||||||
| SNP (gene) | Ref. | Alt. | Control | Case | Control | Case | Comparison | OR (95%CI) | p-value | OR (95%CI) | p-value | ||||||||
|
| |||||||||||||||||||
| rs17047661 (CR1) | G | A | 23.6 | 27.6 | 35.6 | 51.7 |
| 0.887 (0.453, 1.735) | 0.706 | 5.327 (1.733, 16.376) | 0.0008 | ||||||||
| rs2075820 (NOD1) | A | G | 29.2 | 33.9 | 47.1 | 28.3 | Additive G | 1.232 (0.747, 2.031) | 0.238 | 0.364 (0.188, 0.704) | 0.001 | ||||||||
|
| |||||||||||||||||||
| rs3091336 (IL3). | G | A | 25.9 | 37.8 | 20.6 | 27.6 |
| 4.543 (1.900, 10.864) | 0.0007 | 1.553 (1.004, 2.400) | 0.049 | ||||||||
| rs2304081 (SLC22A4) | G | A | 1.6 | 1.2 | 18.3 | 8.3 |
| 0.782 (0.149, 4.100) | 0.767 | 0.342 (0.167, 0.700) | 0.002 | ||||||||
|
| |||||||||||||||||||
| rs3091336 (IL3) | G | A | 25.9 | 35.0 | 20.6 | 26.9 |
| 3.692 (1.579, 8.634) | 0.002 | 1.699 (1.026, 2.810) | 0.03 | ||||||||
| rs2304081 (SLC22A4) | G | A | 1.6 | 2.0 | 18.3 | 7.9 |
| 1.507 (0.446, 5.093) | 0.51 | 0.334 (0.175, 0.635) | 0.0004 | ||||||||
|
| |||||||||||||||||||
| rs112812 (DERL3) | A | G | 49.0 | 30.8 | 43.3 | 45.2 | Additive G | 0.437 (0.257,0.741) | 0.0014 | 0.948 (0.683,1.316) | 0.7496 | ||||||||
|
| |||||||||||||||||||
| rs17047661 (CR1) | G | A | 24.1 | 28.8 | 35.8 | 45.8 |
| 1.098 (0.637,1.893) | 0.7371 | 2.874 (1.505,5.487) | 0.0008 | ||||||||
| rs2304081 (SLC22A4) | G | A | 1.4 | 2.4 | 17.4 | 6.3 |
| 2.360 (0.556,10.014) | 0.2427 | 0.277 (0.120,0.639) | 0.0010 | ||||||||
| rs3212227 (IL12B) | T | G | 34.4 | 40.2 | 29.8 | 30.3 |
| 2.475 (1.399,4.381) | 0.0014 | 1.260 (0.700,2.269) | 0.4397 | ||||||||
| rs569108 (MS4A2) | A | G | 21.8 | 15.4 | 13.2 | 15.5 | Additive G | 0.466 (0.288,0.755) | 0.0011 | 0.907 (0.515,1.600) | 0.7364 | ||||||||
| rs10775349 (ADCY9) | C | G | 12.5 | 13.7 | 40.8 | 44.3 | GC vs other | 1.746 (0.893,3.416) | 0.1043 | 2.471 (1.355,4.506) | 0.0027 | ||||||||
for a vs. GG; Odds ratios (OR), 95% confidence intervals (CI) and p-values based on fitting logistic regression models adjusting for age group and season
Figure 2The log10 p-values from applying SNP association tests for immunological titre phenotypes (from a linear regression adjusted for age and season).
(a) CSP. * dashed line represents a p-value of 0.003, polymorphisms are ordered by chromosome (coloured differently) and position (see Tables S1 and S2). (b) AMA1. * dashed line represents a p-value of 0.003, polymorphisms are ordered by chromosome (coloured differently) and position (see Tables S1 and S2). (c) MSP1. * dashed line represents a p-value of 0.003, polymorphisms are ordered by chromosome (coloured differently) and position (see Tables S1 and S2). (d) MSP2. * dashed line represents a p-value of 0.003, polymorphisms are ordered by chromosome (coloured differently) and position (see Tables S1 and S2). (e) Total IgE. * dashed line represents a p-value of 0.003, polymorphisms are ordered by chromosome (coloured differently) and position (see Tables S1 and S2).
Genetic association tests for (log10 transformed) immunoassay titre phenotypes by ethnic group.
| Alternative allele frequency (%) | Genetic association analysis | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alleles | Dogon | Fulani | |||||||||||
| SNP, Gene | Ref. | Alt. | Dogon | Fulani | Comparison | Effect size (95% CI) | p-value | Effect size (95% CI) | p-value | ||||
| CSP | |||||||||||||
| rs2251746, FCER1A | T | C | 4.9 | 13.1 | CC vs |
|
| 0.933 (-0.229,2.096) | 0.1155 | ||||
| rs3148, IL3 | G | A | 8.8 | 6.4 | AA vs | -0.264 (-1.141,0.612) | 0.5548 |
|
| ||||
| rs1800629, TNF | A | G | 13.4 | 2.1 |
|
|
| 0.031 (-0.191,0.253) | 0.7855 | ||||
| rs3093662, TNF | G | A | 6.4 | 8.5 | AG vs other |
|
| 0.017 (-0.209,0.243) | 0.8806 | ||||
| AMA1 | |||||||||||||
| rs739718, IL5 | T | C | 31.6 | 21.0 | CC vs | 0.163 (-0.163,0.489) | 0.3266 |
|
| ||||
| MSP1 | |||||||||||||
| rs2304081, SLC22A4 | G | A | 1.8 | 15.7 |
| 0.066 (-0.420,0.552) | 0.7907 |
|
| ||||
| rs2070722, IRF1 | G | T | 43.9 | 40.4 | Additive T | 0.001 (-0.134,0.135) | 0.9930 |
|
| ||||
| rs739718, IL5 | T | C | 31.6 | 21.0 | CC vs | 0.162 (-0.194,0.518) | 0.3713 |
|
| ||||
| rs2239704, LTA | G | T | 32.0 | 47.5 |
| 0.005 (-0.180,0.191) | 0.9573 |
|
| ||||
| rs1799964, TNF | T | C | 14.4 | 19.0 | CT vs | -0.075 (-0.288,0.137) | 0.4864 |
|
| ||||
| MSP2 | |||||||||||||
| rs5743809, TLR6 | T | C | 6.0 | 4.8 | CC vs |
|
| -0.570 (-2.167,1.027) | 0.4842 | ||||
| rs35415145, IL3 | C | T | 1.7 | 3.0 | CT vs other | 0.020 (-0.411,0.451) | 0.9267 |
|
| ||||
| rs1799964, TNF | T | C | 14.4 | 19.0 | CT vs other | -0.038 (-0.218,0.143) | 0.6825 |
|
| ||||
| rs1012356, IL22 | T | A | 48.1 | 41.5 |
|
|
| 0.009 (-0.154,0.171) | 0.9160 | ||||
| Total IgE | |||||||||||||
| rs3148, IL3 | G | A | 8.8 | 6.4 | AA vs | -0.006 (-0.506,0.494) | 0.9811 |
|
| ||||
| . rs20541, IL13 | C | T | 27.6 | 7.6 | TT vs |
|
| 1.034 (0.292,1.777) | 0.0063 | ||||
| rs5498, ICAM1 | A | G | 13.7 | 22.9 | Additive G | 0.013 (-0.073,0.100) | 0.7657 |
|
| ||||
Effect sizes (slopes), 95% confidence intervals (CI) and p-values based on fitting linear regression models adjusting for age group and season